The expression of tumor major histocompatibility complex (MHC) classes I and II was examined after treatment; 83.8%, 75.3% and 72.7% of GFAP+/SOX2+ GBM cells expressed MHC class I, MHC class II or both MHC classes I and II, respectively (Fig. 3a). This evidence concerns the gene HLA-C and glioblastoma.